[1]
|
Wang, C., Xu, J., Yang, L., et al. (2018) Prevalence and Risk Factors of Chronic Obstructive Pulmonary Disease in China (the China Pulmonary Health [CPH] Study): A National Cross-Sectional Study. The Lancet, 391, 1706-1717.
https://doi.org/10.1016/S0140-6736(18)30841-9
|
[2]
|
McGregor, H.C., Short, M.A., McWilliams, A., et al. (2017) Real-Time Endoscopic Raman Spectroscopy for in Vivo Early Lung Cancer Detection. Journal of Biophotonics, 10, 98-110. https://doi.org/10.1002/jbio.201500204
|
[3]
|
中国肿瘤临床与康复编辑部. 2017年中国最新癌症数据[J]. 中国肿瘤临床与康复, 2017, 24(6): 760.
|
[4]
|
中华医学会, 中华医学会肿瘤学分会, 中华医学会杂志社. 中华医学会肺癌临床诊疗指南(2018版) [J]. 中华肿瘤杂志, 2018, 40(12): 935-964.
|
[5]
|
Zeneyedpour, L., Dekker, L.J.M., van Sten-van, T., Hoff, J.J.M., et al. (2019) Neoantigens in Chronic Obstructive Pulmonary Disease and Lung Cancer: A Point of View. Proteomics Clinical Applications, 13, e1800093.
https://doi.org/10.1002/prca.201800093
|
[6]
|
徐汉章. 慢性阻塞性肺疾病合并肺癌患者肺功能、免疫功能及营养状态研究[J]. 中国现代药物应用, 2020, 14(6): 46-47.
|
[7]
|
Templeton, A.J., McNamara, M.G., Seruga, B., et al. (2014) Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis. Journal of the National Cancer Institute, 106, dju124.
https://doi.org/10.1093/jnci/dju124
|
[8]
|
Diem, S., Schmid, S., Krapf, M., et al. (2017) Neutrophil-to-Lymphocyteratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) as Prognostic Markers in Patients with Nonsmall Cell Lung Cancer (NSCLC) Treated with Nivolumab. Lung Cancer, 111, 176-181. https://doi.org/10.1016/j.lungcan.2017.07.024
|
[9]
|
Detterbeck, F.C., Boffa, D.J. and Tanoue, L.T. (2009) The New Lung Cancer Staging System. Chest, 136, 260-271.
https://doi.org/10.1378/chest.08-0978
|
[10]
|
Nishino, M., Jackman, D.M., Hatabu, H., et al. (2010) New Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines for Advanced Nonsmall Cell Lung Cancer: Comparison with Original RECIST and Impact on Assessment of Tumor Response to Targeted Therapy. AJR American Journal of Roentgenology, 195, W221-W228.
https://doi.org/10.2214/AJR.09.3928
|
[11]
|
Sears, C.R. (2019) DNA Repair as an Emerging Target for COPD-Lung Cancer Overlap. Respiratory Investigation, 57, 111-121. https://doi.org/10.1016/j.resinv.2018.11.005
|
[12]
|
Koshiol, J., Rotunno, M., Consonni, D., et al. (2009) Chronic Obstructive Pulmonary Disease and Altered Risk of Lung Cancer in a Population-Based Case-Control Study. PLoS ONE, 4, e7380.
https://doi.org/10.1371/journal.pone.0007380
|
[13]
|
王学林. 慢性阻塞性肺疾病合并肺癌的临床特点分析[J]. 临床医学, 2019, 39(2): 27-28.
|
[14]
|
王丹, 庞敏. 慢性阻塞性肺疾病合并肺癌的临床特征分析[J]. 临床肺科杂志, 2019, 24(6): 1082-1085.
|
[15]
|
胡洁, 白春学. 肺癌的规范化治疗[J]. 内科急危重症杂志, 2014, 20(5): 294-298.
|
[16]
|
Sekine, Y., Katsura, H., Koh, E., et al. (2012) Early Detection of COPD Is Important for Lung Cancer Surveillance. European Respiratory Journal, 39, 1230. https://doi.org/10.1183/09031936.00126011
|
[17]
|
Durham, A.L. and Adcock, I.M. (2015) The Relationship between COPD and Lung Cancer. Lung Cancer, 90, 121-127.
https://doi.org/10.1016/j.lungcan.2015.08.017
|
[18]
|
Chen, L., Kong, X., Yan, C., et al. (2020) The Research Progress on the Prognostic Value of the Common Hematological Parameters in Peripheral Venous Blood in Breast Cancer. OncoTargets and Therapy, 13, 1397-1412.
https://doi.org/10.2147/OTT.S227171
|
[19]
|
Miyamoto, R., Inagawa, S., Sano, N., et al. (2018) The Neutrophil-to-Lymphocyte Ratio (NLR) Predicts Short-Term and Long-Term Outcomes in Gastric Cancer Patients. European Journal of Surgical Oncology, 44, 607-612.
https://doi.org/10.1016/j.ejso.2018.02.003
|
[20]
|
Zhang, J., Zhang, H.Y., Li, J., et al. (2017) The Elevated NLR, PLR and PLT May Predict the Prognosis of Patients with Colorectal Cancer: A Systematic Review and Meta-Analysis. Oncotarget, 8, 68837-68846.
https://doi.org/10.18632/oncotarget.18575
|
[21]
|
Iimori, N., Kashiwagi, S., Asano, Y., et al. (2018) Clinical Significance of the Neutrophil-to-Lymphocyte Ratio in Endocrine Therapy for Stage IV Breast Cancer. In Vivo, 32, 669-675. https://doi.org/10.21873/invivo.11292
|
[22]
|
Yao, Y., Yuan, D., Liu, H., et al. (2013) Pretreatment Neutrophil to Lymphocyte Ratio Is Associated with Response to Therapy and Prognosis of Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Platinum-Based Chemotherapy. Cancer Immunology, Immunotherapy, 62, 471-479. https://doi.org/10.1007/s00262-012-1347-9
|
[23]
|
Peng, B., Wang, Y.H., Liu, Y.M., et al. (2015) Prognostic Significance of the Neutrophil to Lymphocyte Ratio in Patients with Non-Small Cell Lung Cancer: A Systemic Review and Meta-Analysis. International Journal of Clinical and Experimental Medicine, 8, 3098-3106.
|
[24]
|
Botta, C., Barbieri, V., Ciliberto, D., et al. (2013) Systemic Inflammatory Status at Baseline Predicts Bevacizumab Benefit in Advanced Non-Small Cell Lung Cancer Patients. Cancer Biology & Therapy, 14, 469-475.
https://doi.org/10.4161/cbt.24425
|
[25]
|
李曦颖, 黄礼年. 动态监测NLR、PLR变化与晚期肺腺癌一线化疗疗效及预后关系[J]. 蚌埠医学院学报, 2020, 45(11): 1486-1490.
|
[26]
|
Li, X., Zeng, W.H., Zhou, Y.Q., et al. (2019) Neutrophil-to-Lymphocyte Ratio Predicted Long-Term Chemotherapy Benefits in Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer Patients without Sensitive Mutations. OncoTargets and Therapy, 12, 8779-8787. https://doi.org/10.2147/OTT.S225544
|
[27]
|
Vaguliene, N., Zemaitis, M., Lavinskiene, S., et al. (2013) Local and Systemic Neutrophilic Inflammation in Patients with Lung Cancer and Chronic Obstructive Pulmonary Disease. BMC Immunology, 14, 36.
https://doi.org/10.1186/1471-2172-14-36
|
[28]
|
易福梅, 顾阳春, 陈森, 刘燕娥, 尹文琤, 张煜, 曹宝山. 治疗前后NLR和PLR对进展期非小细胞肺癌一线化疗疗效及预后的预测价值[J]. 中国肺癌杂志, 2018, 21(6): 481-492.
|